Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Nutrition Groups Challenge EFSA Health Claims Policy

This article was originally published in The Tan Sheet

Executive Summary

European industry trade associations file a lawsuit to block the implementation of what they call EFSA’s restrictive list of permitted health claims. The groups demand the annulment of the general function claim list and ask the EC to “correct the flaws in its approach.”

You may also be interested in...



Ganeden Claims “Highest Level” Proof For Anti-Aging Probiotic

Ganeden Biotech is optimistic that evidence backing the efficacy of its anti-aging probiotic Bonicel will drive success of the branded ingredient. As regulators and lawsuits target cosmetics companies over claims, science that can withstand these tests becomes more important.

Ganeden Claims “Highest Level” Proof For Anti-Aging Probiotic

Ganeden Biotech is optimistic that evidence backing the efficacy of its anti-aging probiotic Bonicel will drive success of the branded ingredient. As regulators and lawsuits target cosmetics companies over claims, science that can withstand these tests becomes more important.

Harmonization Eyed For EU Botanical Claim Regs, With Tighter Scrutiny

Two options are touted for botanical claims legislation in the EU – one would continue with the existing process under the European Food Safety Authority’s evaluation of claims for all types of supplement products and the other would align botanical regs with the medicines sector.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel